Market Closed -
Xetra
11:36:55 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
28.24
EUR
|
+0.66%
|
|
+2.21%
|
-16.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
71,530
|
47,309
|
46,174
|
47,476
|
33,039
|
27,744
|
-
|
-
|
Enterprise Value (EV)
1 |
105,598
|
84,884
|
79,140
|
78,749
|
67,302
|
61,746
|
58,235
|
54,836
|
P/E ratio
|
17.5
x
|
-4.51
x
|
46.1
x
|
11.5
x
|
-11.2
x
|
12.4
x
|
8.66
x
|
8.28
x
|
Yield
|
3.85%
|
4.15%
|
4.26%
|
4.97%
|
0.33%
|
0.39%
|
0.77%
|
3.87%
|
Capitalization / Revenue
|
1.64
x
|
1.14
x
|
1.05
x
|
0.94
x
|
0.69
x
|
0.59
x
|
0.58
x
|
0.57
x
|
EV / Revenue
|
2.43
x
|
2.05
x
|
1.8
x
|
1.55
x
|
1.41
x
|
1.31
x
|
1.22
x
|
1.13
x
|
EV / EBITDA
|
9.18
x
|
7.41
x
|
7.08
x
|
5.83
x
|
6.33
x
|
5.92
x
|
5.38
x
|
4.99
x
|
EV / FCF
|
19
x
|
34.2
x
|
31.9
x
|
19
x
|
28.4
x
|
18.3
x
|
11.9
x
|
12.5
x
|
FCF Yield
|
5.26%
|
2.93%
|
3.13%
|
5.26%
|
3.52%
|
5.47%
|
8.39%
|
8.02%
|
Price to Book
|
1.51
x
|
1.55
x
|
1.4
x
|
1.22
x
|
1
x
|
0.82
x
|
0.74
x
|
0.67
x
|
Nbr of stocks (in thousands)
|
982,424
|
982,424
|
982,424
|
982,424
|
982,424
|
982,424
|
-
|
-
|
Reference price
2 |
72.81
|
48.16
|
47.00
|
48.32
|
33.63
|
28.24
|
28.24
|
28.24
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
43,545
|
41,400
|
44,081
|
50,739
|
47,637
|
47,119
|
47,903
|
48,603
|
EBITDA
1 |
11,503
|
11,461
|
11,179
|
13,513
|
10,632
|
10,426
|
10,828
|
10,987
|
EBIT
1 |
7,007
|
7,095
|
7,295
|
9,257
|
7,589
|
6,673
|
7,051
|
7,205
|
Operating Margin
|
16.09%
|
17.14%
|
16.55%
|
18.24%
|
15.93%
|
14.16%
|
14.72%
|
14.82%
|
Earnings before Tax (EBT)
1 |
2,880
|
-17,250
|
2,046
|
4,670
|
-1,621
|
3,786
|
4,026
|
4,364
|
Net income
1 |
4,091
|
-10,495
|
1,000
|
4,150
|
-2,941
|
2,334
|
3,179
|
3,394
|
Net margin
|
9.39%
|
-25.35%
|
2.27%
|
8.18%
|
-6.17%
|
4.95%
|
6.64%
|
6.98%
|
EPS
2 |
4.170
|
-10.68
|
1.020
|
4.220
|
-2.990
|
2.285
|
3.260
|
3.410
|
Free Cash Flow
1 |
5,557
|
2,485
|
2,478
|
4,144
|
2,366
|
3,376
|
4,884
|
4,395
|
FCF margin
|
12.76%
|
6%
|
5.62%
|
8.17%
|
4.97%
|
7.17%
|
10.19%
|
9.04%
|
FCF Conversion (EBITDA)
|
48.31%
|
21.68%
|
22.17%
|
30.67%
|
22.25%
|
32.38%
|
45.1%
|
40.01%
|
FCF Conversion (Net income)
|
135.83%
|
-
|
247.8%
|
99.86%
|
-
|
144.63%
|
153.64%
|
129.51%
|
Dividend per Share
2 |
2.800
|
2.000
|
2.000
|
2.400
|
0.1100
|
0.1110
|
0.2174
|
1.092
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2020 S2
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
22,899
|
18,501
|
11,118
|
14,639
|
12,819
|
11,281
|
12,000
|
14,389
|
11,044
|
10,342
|
11,862
|
13,765
|
11,052
|
24,831
|
10,376
|
11,963
|
22,454
|
-
|
-
|
EBITDA
1 |
7,274
|
-
|
2,395
|
5,251
|
3,349
|
2,451
|
2,462
|
4,471
|
2,527
|
1,685
|
3,023
|
4,412
|
2,337
|
6,738
|
1,569
|
2,337
|
3,941
|
-
|
-
|
EBIT
1 |
-
|
-
|
1,383
|
4,172
|
2,280
|
1,352
|
1,453
|
3,404
|
1,534
|
709
|
1,942
|
3,299
|
1,269
|
-
|
788.9
|
1,280
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
12.44%
|
28.5%
|
17.79%
|
11.98%
|
12.11%
|
23.66%
|
13.89%
|
6.86%
|
16.37%
|
23.97%
|
11.48%
|
-
|
7.6%
|
10.7%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
1,497
|
3,722
|
-523
|
601
|
870
|
2,606
|
-1,574
|
-4,297
|
1,644
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-
|
-
|
1,161
|
3,291
|
-298
|
546
|
611
|
2,178
|
-1,887
|
-4,569
|
1,337
|
2,000
|
84.53
|
-
|
-305.8
|
-201.4
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
10.44%
|
22.48%
|
-2.32%
|
4.84%
|
5.09%
|
15.14%
|
-17.09%
|
-44.18%
|
11.27%
|
14.53%
|
0.76%
|
-
|
-2.95%
|
-1.68%
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
1.180
|
3.350
|
-0.3000
|
0.5600
|
0.6200
|
2.220
|
-1.920
|
-4.660
|
1.360
|
2.040
|
0.0854
|
-
|
-0.3110
|
-0.2052
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
2.000
|
-
|
-
|
-
|
2.400
|
-
|
-
|
-
|
0.1100
|
-
|
0.0275
|
-
|
0.0275
|
0.0275
|
-
|
0.0275
|
0.0275
|
Announcement Date
|
8/4/20
|
2/25/21
|
3/1/22
|
5/10/22
|
8/4/22
|
11/8/22
|
2/28/23
|
5/11/23
|
8/8/23
|
11/8/23
|
3/5/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
34,068
|
37,575
|
32,966
|
31,273
|
34,263
|
34,002
|
30,491
|
27,092
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.962
x
|
3.279
x
|
2.949
x
|
2.314
x
|
3.223
x
|
3.261
x
|
2.816
x
|
2.466
x
|
Free Cash Flow
1 |
5,557
|
2,485
|
2,478
|
4,144
|
2,366
|
3,376
|
4,884
|
4,395
|
ROE (net income / shareholders' equity)
|
13.5%
|
16.2%
|
20.1%
|
8.65%
|
17.5%
|
14.5%
|
15%
|
13.5%
|
ROA (Net income/ Total Assets)
|
3.23%
|
-8.63%
|
0.84%
|
3.39%
|
-2.44%
|
0.73%
|
1.55%
|
2.62%
|
Assets
1 |
126,495
|
121,611
|
118,526
|
122,560
|
120,567
|
319,156
|
204,993
|
129,465
|
Book Value Per Share
2 |
48.20
|
31.10
|
33.60
|
39.50
|
33.50
|
34.50
|
38.30
|
42.30
|
Cash Flow per Share
2 |
8.360
|
4.990
|
5.180
|
7.220
|
5.210
|
6.210
|
8.350
|
8.320
|
Capex
1 |
2,650
|
2,418
|
2,611
|
2,949
|
2,751
|
2,996
|
2,912
|
2,987
|
Capex / Sales
|
6.09%
|
5.84%
|
5.92%
|
5.81%
|
5.77%
|
6.36%
|
6.08%
|
6.15%
|
Announcement Date
|
2/27/20
|
2/25/21
|
3/1/22
|
2/28/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
28.24
EUR Average target price
36.64
EUR Spread / Average Target +29.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.03% | 30.09B | | +40.73% | 739B | | +32.83% | 598B | | -6.30% | 353B | | +15.15% | 318B | | +4.05% | 285B | | +15.00% | 240B | | +9.78% | 210B | | -5.52% | 206B | | +6.17% | 164B |
Other Pharmaceuticals
|